Analyzing Parallax Health Sciences (OTCMKTS:PRLX) & Mesa Laboratories (NASDAQ:MLAB)

Mesa Laboratories (NASDAQ:MLAB) and Parallax Health Sciences (OTCMKTS:PRLX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares Mesa Laboratories and Parallax Health Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.72%	9.82%
Parallax Health Sciences	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Mesa Laboratories and Parallax Health Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0	3	0	0	2.00
Parallax Health Sciences	0	0	0	0	0.00

Mesa Laboratories currently has a consensus price target of $110.00, indicating a potential downside of 13.25%. Given Parallax Health Sciences’ higher probable upside, analysts clearly believe Parallax Health Sciences is more favorable than Mesa Laboratories.

Insider & Institutional Ownership

90.6% of Mesa Laboratories shares are held by institutional investors. 2.8% of Mesa Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Mesa Laboratories and Parallax Health Sciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.72 million	2.84	$6.71 million	$0.84	150.96
Parallax Health Sciences	N/A	N/A	N/A	N/A	N/A

Mesa Laboratories has higher revenue and earnings than Parallax Health Sciences.

Summary

Mesa Laboratories beats Parallax Health Sciences on 7 of the 8 factors compared between the two stocks.

About Mesa Laboratories

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

About Parallax Health Sciences

Parallax Health Sciences, Inc. is an integrated digital healthcare company. It is engaged in the provision of personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care diagnostic testing. The firm operates through the following segments: Remote Patient Monitoring, Behavioral Health Systems, and Corporate. The Remote Patient Monitoring segment offers a technology platform that includes a complete remote patient care delivery system through PHM. The Behavioral Health Systems segment includes the intellectual property, Reliable Evidence-Based Outcomes Optimization Technologies, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc. The Corporate segment consists of management and administrative services. The company was founded on July 6, 2005 and is headquartered in Los Angeles, CA.